Conversely, an Italian study found that short-termadministration of L-SeMet (166 μg/day orally for six months) had alimited effect on the progression of Hashimoto’s thyroiditis (HT), as indicatedby unchanged levels of TSH, TPOAb, and CXCL10, a chemokine crucial to the immunepathogenesis of HT (71). This evidence concerns the gene CXCL10 and hematocrit.